Sirolimus- vs. paclitaxel-eluting stents for the treatment of unprotected left main coronary artery stenosis: Complete 2-year follow-up of a two-center registry

Park, Kyung Woo; Kang, Sang‐Won; Park, Keun-Ho; Choi, Dong‐Hyun; Lee, Hae Young; Kang, Hyun–Jae; Cho, Young-Seok; Yeon, Tae-Jin; Chung, Woo-Young; Koo, Bon‐Kwon; Chae, In‐Ho; Choi, Dong‐Ju; Oh, Byung Hee; Park, Young-Bae; Kim, Hyo–Soo

doi:10.1016/j.ijcard.2010.05.001

Cited by 8 publications

(8 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[3] There are several explanations for this finding. First, the low frequency of follow-up angiography may underestimate the incidence of in-stent restenosis.…”

Section: Discussionmentioning

confidence: 99%

“…Though some studies [7,8] have found that DES could increase the risk of late stent thrombosis, clinical trails have proved that DES could significantly improve the long-term prognosis of patients with CHD. [3,4,[8][9][10] Since domestic DES Firebird was marketed in 2003, several other types of domestic DES have been put into clinical practice. With the improvement of manufacturing technology of domestic DESs, they have been used clinically in recent years.…”

Section: Discussionmentioning

confidence: 99%

“…[2] The wide use of DES has made it possible for the treatment of complex coronary lesions with PCI, and the clinical effect of imported DES has been proved by numerous clinical trials. [3][4][5] After domestic DES, Firebird, was put into use, other DESs have been developed. With the improvement of manufacturing technology of domestic stents and interventional techniques, domestic DESs have been widely used in clinical practice.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Domestic versus imported drug-eluting stents for the treatment of patients with acute coronary syndrome

Yao

Sun

Wan

et al. 2014

World Journal of Emergency Medicine

View full text Add to dashboard Cite

BACKGROUND:The application of coronary stents, especially drug-eluting stents (DESs), has made percutaneous coronary intervention (PCI) one of important therapeutic methods for CHD. DES has reduced the in-stent restenosis to 5%-9% and signifi cantly improved the long-term prognosis of patients with CHD. The study aimed to investigate the long-term effi cacy and safety of domestic drugeluting stents (DESs) in patients with acute coronary syndrome (ACS).METHODS: All patients with ACS who had undergone successful percutaneous coronary intervention (PCI) in the First Affi liated Hospital of Zhengzhou University from July 2009 to December 2010 were included in this study. Patients were excluded from the study if they were implanted with bare metal stents or different stents (domestic and imported DESs) simultaneously. The included patients were divided into two groups according to different stents implanted: domestic DESs and imported DESs. RESULTS:In the 1 683 patients of this study, 1 558 (92.6%) patients were followed up successfully for an average of (29.1±5.9) months. 130 (8.3%) patients had major adverse cardiovascular events (MACEs), including cardiac death in 32 (2.1%) patients, recurrent myocardial infarction in 16 (1%), and revascularization in 94 (6%). The rates of cardiac death, recurrent myocardial infarction, revascularization, in-stent restenosis, stent thrombosis and other MACEs were not signifi cantly different between the two groups (all P>0.05). Multivarite logistic regression revealed that diabetes mellitus (OR=1.75, 95%CI: 1.09-2.82, P=0.021), vascular numbers of PCI (OR=2.16, P=0.09) and PCI with left main lesion (OR=9.47, P=0.01) were independent prognostic factors of MACEs. The Kaplan-Meier method revealed that there was no significant difference in cumulative survival rates and survival rates free from clinical events between the two groups (all P>0.05). CONCLUSIONS:The incidences of clinical events and cumulative survival rates are not statistically different between domestic DESs and imported DESs. Domestic DES is effective and safe in the treatment of patients with ACS.

show abstract

“…[3] There are several explanations for this finding. First, the low frequency of follow-up angiography may underestimate the incidence of in-stent restenosis.…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Domestic versus imported drug-eluting stents for the treatment of patients with acute coronary syndrome

Yao

Sun

Wan

et al. 2014

World Journal of Emergency Medicine

View full text Add to dashboard Cite

show abstract

“…We read with interest the paper by Park et al [1]. The authors conclude that, in the treatment of left main coronary artery (LMCA) stenosis, paclitaxel eluting stents (PES) and sirolimus eluting stents (SES) provide comparable 2 year-clinical results with respect to hard endpoints and major adverse cardiac events.…”

mentioning

confidence: 98%

“…

We read with interest the paper by Park et al [1]. The authors conclude that, in the treatment of left main coronary artery (LMCA) stenosis, paclitaxel eluting stents (PES) and sirolimus eluting stents (SES) provide comparable 2 year-clinical results with respect to hard endpoints and major adverse cardiac events.

This finding might be interpreted with caution by the readers of the Journal, in relation to the previous literature concerning the SES and PES and to the inherent limitations of the study.

Several studies [2,3] have already showed that SES are superior to PES in terms of reduction of clinical events .

…”

mentioning

confidence: 99%

"Sirolimus or paclitaxel drug eluting stent in left main disease: The winner is… "

Navarese

Kubica

Gurbel

2011

International Journal of Cardiology

View full text Add to dashboard Cite

Response to "Sirolimus or paclitaxel drug eluting stent in left main disease: The winner is…"

Park

Kang

Kim

2012

International Journal of Cardiology

Self Cite

View full text Add to dashboard Cite

Sirolimus- vs. paclitaxel-eluting stents for the treatment of unprotected left main coronary artery stenosis: Complete 2-year follow-up of a two-center registry

Cited by 8 publications

References 25 publications

Domestic versus imported drug-eluting stents for the treatment of patients with acute coronary syndrome

Domestic versus imported drug-eluting stents for the treatment of patients with acute coronary syndrome

"Sirolimus or paclitaxel drug eluting stent in left main disease: The winner is… "

Response to "Sirolimus or paclitaxel drug eluting stent in left main disease: The winner is…"

Contact Info

Product

Resources

About